Navidea Biopharmaceuticals Inc (OTCPK:NAVB)
$ 0.035 -0.0042 (-10.71%) Market Cap: 3.50 Mil Enterprise Value: 1.32 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 0/100

Navidea Biopharmaceuticals, Inc - Special Call Transcript

Apr 08, 2019 / 09:00PM GMT
Release Date Price: $3.4 (+21.43%)
Operator

Greetings, and welcome to the Navidea Biopharmaceuticals FDA update on rheumatoid arthritis trial call. (Operator Instructions) Please note, this conference is being recorded.

I will now turn the conference over to your host, Jed Latkin, the CEO. Mr. Latkin, you may begin.

Jed A. Latkin
Navidea Biopharmaceuticals, Inc - CEO, COO, CFO, Secretary, Treasurer & Director

Thank you, Omar. Good afternoon, and welcome, everyone, to Navidea's conference call to discuss the press release that we issued this morning concerning a clinical update regarding our rheumatoid arthritis clinical trial design.

I'm Jed Latkin, Chief Executive Officer of Navidea Biopharmaceuticals. This call will provide further commentary and details concerning today's press release. Following our prepared remarks, we will open up the conference call to a question-and-answer session.

With me on our call today are several members of the Navidea senior management team, including Chief Medical Officer, Dr. Michael Rosol, and our Chief Compliance and Regulatory Officer

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot